The clinical use of bone resorption markers in patients with malignant bone disease
暂无分享,去创建一个
[1] P. Garnero. Markers of bone turnover in prostate cancer. , 2001, Cancer treatment reviews.
[2] R E Coleman,et al. Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.
[3] M. Koizumi,et al. The serum level of the amino‐terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone , 2001, BJU international.
[4] L. Rosen,et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] J. Berenson,et al. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease , 2001, Cancer.
[6] T. Tomomitsu,et al. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy , 2001, Journal of Bone and Mineral Metabolism.
[7] B. Hillner,et al. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .
[8] G. Hortobagyi,et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.
[9] R. Rizzoli,et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.
[10] P. Ross,et al. Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study , 2000, Osteoporosis International.
[11] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Souberbielle,et al. Bone markers in clinical practice. , 1999, Current opinion in rheumatology.
[13] R. Ziegler,et al. Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] A. Howell,et al. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases , 1999, British Journal of Cancer.
[15] D. Lacombe,et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion , 1999, British Journal of Cancer.
[16] L. Alvarez,et al. [The clinical utility of biochemical markers of bone remodeling]. , 1999, Medicina clinica.
[17] T. Yoneda,et al. Bisphosphonates as anticancer drugs. , 1999, The New England journal of medicine.
[18] G. Hortobagyi,et al. Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.
[19] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[20] V. Castronovo,et al. Ectopic expression of bone sialoprotein in human thyroid cancer. , 1998, Thyroid : official journal of the American Thyroid Association.
[21] V. Castronovo,et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. , 1998, Journal of the National Cancer Institute.
[22] G. Hortobagyi,et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Tsushima,et al. Protein kinase C (PKC)-mediated growth hormone (GH) actions. , 1998, Endocrine journal.
[24] A. Zwinderman,et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. , 1998, Bone.
[25] R. Bell,et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Y. Furuya,et al. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. , 1998, Endocrine journal.
[27] R. Eastell,et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R H Christenson,et al. Biochemical markers of bone metabolism: an overview. , 1997, Clinical biochemistry.
[29] M. Seibel,et al. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. , 1997, Clinical chemistry.
[30] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[31] M. Takada,et al. Diagnostic validity of bone metabolic markers for bone metastasis. , 1997, Endocrine journal.
[32] P. Delmas,et al. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. , 1997, British Journal of Cancer.
[33] R. Eastell,et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Reinauer,et al. Bone sialoprotein in serum of patients with malignant bone diseases. , 1997, Clinical chemistry.
[35] G. Hortobagyi,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.
[36] N. Abildgaard,et al. Assessment of bone involvement in patients with multiple myeloma using bone densitometry , 1996, European journal of haematology.
[37] S. Ménard,et al. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival , 1996, International journal of cancer.
[38] R. Eastell,et al. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.
[39] D. Mcnulty,et al. Proteolytic Activity of Human Osteoclast Cathepsin K , 1996, The Journal of Biological Chemistry.
[40] C. Debouck,et al. Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.
[41] V. Castronovo,et al. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] R. Eastell,et al. Metabolic effects of pamidronate in patients with metastatic bone disease. , 1996, British Journal of Cancer.
[43] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.
[44] C. Christiansen,et al. Effect of bisphosphonate therapies (pamidronate and ibandronate) on the excretion of degradation products of the C-telopeptides of type I collagen measured by a radioimmunoassay (crosslap™ ria) , 1995 .
[45] V. Chinchilli,et al. Biochemical markers of bone turnover in patients with metastatic bone disease. , 1995, Clinical chemistry.
[46] M. Piccart,et al. Intravenous pamidronate in patients with tumor‐induced osteolysis: A biochemical dose‐response study , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[47] I. Yamamoto,et al. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers]. , 1995, Kaku igaku. The Japanese journal of nuclear medicine.
[48] T. Tammela,et al. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. , 1995, British Journal of Cancer.
[49] J. Kanis,et al. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] R. Rubens,et al. The systemic treatment of bone metastases. , 1995, Clinical orthopaedics and related research.
[51] T. Schilling,et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. , 1995, The Journal of clinical endocrinology and metabolism.
[52] A. Lipton,et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study , 1994, Cancer.
[53] C. Christiansen,et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. , 1994, Clinical chemistry.
[54] H. Woitge,et al. Direct, enzyme‐linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[55] M. Seibel,et al. O8. A direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption , 1994 .
[56] V. Castronovo,et al. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. , 1994, Cancer research.
[57] R. Baron,et al. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. , 1993, Journal of cell science.
[58] P. Ravaud,et al. Bone densitometry in patients with multiple myeloma. , 1992, The American journal of medicine.
[59] D. Eyre,et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[60] J. Bilezikian,et al. Urinary pyridinium crosslinks of collagen Specific markers of bone resorption in metabolic bone disease , 1992, Trends in Endocrinology & Metabolism.
[61] R. Rubens,et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. , 1992, British Journal of Cancer.
[62] G. Hortobagyi. Bone metastases in breast cancer patients. , 1991, Seminars in oncology.
[63] C. Christiansen,et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[64] R. Coleman. Assessment of Response to Treatment , 1991 .
[65] D. W. Moss,et al. Bone scan flare predicts successful systemic therapy for bone metastases. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] D. W. Moss,et al. Biochemical prediction of response of bone metastases to treatment. , 1988, British Journal of Cancer.
[67] J. Reeve,et al. Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. , 1988, Clinica chimica acta; international journal of clinical chemistry.
[68] C. Blomqvist,et al. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism , 1987, Cancer.
[69] R. Rubens,et al. The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.
[70] T. Bringman,et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors , 1986, Nature.
[71] T. Powles,et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer , 1983, Cancer.
[72] R. Blamey,et al. Calcium excretion (CaE) in metastatic breast cancer , 1983, The British journal of surgery.
[73] R. Wootton,et al. The clinical measurement of urinary total hydroxyproline excretion. , 1979, Clinica chimica acta; international journal of clinical chemistry.
[74] B. Courvoisier,et al. Total urinary and free serum hydroxyproline in metastatic bone disease. , 1979, British Journal of Cancer.
[75] Mautalen Ca. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. , 1970 .
[76] C. Mautalen. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. , 1970, The Journal of laboratory and clinical medicine.
[77] M. Peacock,et al. Relation between serum and urinary calcium with particular reference to parathyroid activity. , 1969, Lancet.